Presentation is loading. Please wait.

Presentation is loading. Please wait.

Osteopontin Combined With CD44v6, a Novel Prognostic Biomarker in Non-Small Cell Lung Cancer Undergoing Curative Resection  Bing-sheng Sun, MD, PhD, Yue.

Similar presentations


Presentation on theme: "Osteopontin Combined With CD44v6, a Novel Prognostic Biomarker in Non-Small Cell Lung Cancer Undergoing Curative Resection  Bing-sheng Sun, MD, PhD, Yue."— Presentation transcript:

1 Osteopontin Combined With CD44v6, a Novel Prognostic Biomarker in Non-Small Cell Lung Cancer Undergoing Curative Resection  Bing-sheng Sun, MD, PhD, Yue Li, MD, Zhen-fa Zhang, MD, PhD, Jian You, MD, PhD, Chang-li Wang, MD, PhD  The Annals of Thoracic Surgery  Volume 96, Issue 6, Pages (December 2013) DOI: /j.athoracsur Copyright © 2013 The Society of Thoracic Surgeons Terms and Conditions

2 Fig 1 Typical photomicrographs show expression of osteopontin (OPN) and CD44 immunohistochemistry in tissue microarray. Diaminobenzidine solution is the stain used in all images. (A) OPN+ (original magnification × 40); (B) OPN+ (original magnification ×100); (C) OPN– (original magnification ×40); (D) OPN– (original magnification ×100; (E) CD44v6+ (original magnification ×40); (F) CD44v6+ (original magnification ×100); (G) CD44v6– (original magnification ×40); and (H) CD44v6– (original magnification ×100). The Annals of Thoracic Surgery  , DOI: ( /j.athoracsur ) Copyright © 2013 The Society of Thoracic Surgeons Terms and Conditions

3 Fig 2 Prognostic significance assessed using Kaplan-Meier survival estimates and log-rank tests. Comparisons are shown of overall survival and disease-free survival (DFS) by (A and B) osteopontin (OPN) and (C and D) CD44v6. The Annals of Thoracic Surgery  , DOI: ( /j.athoracsur ) Copyright © 2013 The Society of Thoracic Surgeons Terms and Conditions

4 Fig 3 Kaplan-Meier analysis of (A) overall survival and (B) disease-free survival for combined osteopontin (OPN) and CD44v6. The Annals of Thoracic Surgery  , DOI: ( /j.athoracsur ) Copyright © 2013 The Society of Thoracic Surgeons Terms and Conditions

5 Fig 4 Kaplan-Meier analysis shows (A) overall survival and (B) disease-free survival for combined osteopontin (OPN) and CD44v6 in non-small cell lung cancer patients at stage I. The Annals of Thoracic Surgery  , DOI: ( /j.athoracsur ) Copyright © 2013 The Society of Thoracic Surgeons Terms and Conditions


Download ppt "Osteopontin Combined With CD44v6, a Novel Prognostic Biomarker in Non-Small Cell Lung Cancer Undergoing Curative Resection  Bing-sheng Sun, MD, PhD, Yue."

Similar presentations


Ads by Google